Protara climbs on FDA's 'fast track' tag for nutritional therapy

Protara Therapeutics

21/10/2024 14:11

** Shares of therapy developer Protara Therapeutics  TARA.O 
rise ~2.6% to $1.96 premarket
    ** Co says its IV choline chloride therapy, used to give
choline for adult and adolescent patients on parenteral support,
received the U.S. FDA's "fast track" designation
    ** People on parenteral support are unable to gain nutrients
orally and receive them through a catheter placed in a vein 
    ** FDA's "fast track" status facilitates the development and
expedites the review of medicines to treat serious conditions
    ** Up to last close, stock up 1.9% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))